This change is happening because there’s another covered medication that’s safe and effective for your condition and may cost ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Taylor Fritz blames opponent for Wimbledon curfew controversy after match suspended A trucker in his late 70s who can't ...

Summary. Eli Lilly and Company's stock fell over 11% after CVS Caremark excluded Lilly’s obesity drug Zepbound from its standard commercial formularies starting July 1, 2025.

CVS opts for Wegovy over Zepbound, affecting drug access for some. CVS Health also said Thursday that it will start selling Wegovy at a discounted price of about $500 monthly at thousands of ...

CVS's pharmacy benefit management unit, the largest in the U.S., said it would drop Zepbound coverage from July 1, but keep reimbursing for Wegovy after negotiating a more favorable price from the ...

Wegovy will now be the GLP-1 weight loss drug of choice under plans that are managed by CVS Caremark. If they stay on Zepbound for their GLP-1 weight loss treatment, they will have to pay full ...